Age-Related Macular Degeneration (ARMD) Completed Phase 3 Trials for Ranibizumab (DB01270)

Also known as: Age-related macular degeneration / Macular Degeneration / Senile macular degeneration / Macular degeneration senile / Macular degeneration (senile) of retina, unspecified

IndicationStatusPhase
DBCOND0034150 (Age-Related Macular Degeneration (ARMD))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03150589A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)Treatment
NCT01570608Lucentis KAV StudyTreatment
NCT01170767French Evaluation Group Avastin Versus LucentisTreatment
NCT00826371Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) PatientsTreatment
NCT00331864SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular DegenerationTreatment
NCT00275821Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)Treatment
NCT01948830Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMDSupportive Care
NCT00891735A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)Treatment
NCT00251459A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)Treatment
NCT00429962Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNVTreatment
NCT00470678EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)Treatment